Company Interview / Avecho's dream partnership with Sandoz to target insomnia

Key points:

Avecho's phase three trial of CBD capsule targets insomnia.Exclusive licensing with Sandoz enhances Australian market potential.Interim analysis funds secured; market release anticipated by 2027-2028.

Paul Gavin of Avecho Biotechnology (ASX: AVE) discusses the company’s progress with their proprietary CBD soft gel capsule aimed at treating insomnia. The phase three trial, which is underway, could lead to the first registered pharmaceutical CBD product for insomnia. A successful outcome is seen as commercially promising.

Paul mentions an exclusive licensing and development agreement with Sandoz, a Swiss multinational. This collaboration allows Sandoz to manage Australian rights, enhancing the product's market potential. Avecho retains licensing rights for the rest of the world, opening up further international opportunities.

Current financial support from Sandoz, including a 4.8 million AUD upfront payment, ensures funding for an interim analysis of the trial. Paul indicates confidence in securing additional capital post-analysis. The approved timeline predicts market availability around 2027-2028, contingent upon regulatory approval.